MEDI 9287

Drug Profile

MEDI 9287

Alternative Names: Avian influenza vaccine - AstraZeneca; H7N9 vaccine - AstraZeneca; Influenza A virus vaccine H7N9 - AstraZeneca; MEDI-9287

Latest Information Update: 01 Sep 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; National Institute of Allergy and Infectious Diseases
  • Class Influenza A virus H7N9 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza A virus H7N9 subtype

Most Recent Events

  • 31 Jul 2014 Discontinued - Phase-I for Influenza-A virus H7N9 subtype in USA (unspecified route)
  • 31 Mar 2014 AstraZeneca establishes CRADA with NIH for the development of MEDI 9287 in Influenza A virus H7N9 subtype prior to March 2014
  • 12 Dec 2013 Phase-I clinical trials in Influenza-A virus H7N9 subtype in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top